A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Clinical trial NCT06333860 · COMPLETED

Trial details

NCT number: NCT06333860
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Moderate Plaque Psoriasis

Start date: 2024-05-10
Primary completion: 2026-03-19
Enrollment: 393

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.